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Summary  Intravenous  sedation  is  effective  to  reduce  fear  and  anxiety  in  dental  treatment.
It also  has  been  used  for  behavior  modification  technique  in  dental  patients  with  special  needs.
Midazolam and  propofol  are  commonly  used  for  intravenous  sedation.  Although  there  have
been many  researches  on  the  effects  of  midazolam  and  propofol  on  vital  function  and  the
recovery  profile,  little  is  known  about  muscle  power.  This  review  discusses  the  effects  of  intra-
venous sedation  using  midazolam  and  propofol  on  both  grip  strength  and  bite  force.  During  light
propofol sedation,  grip  strength  increases  slightly  and  bite  force  increases  in  a  dose-dependent
manner.  Grip  strength  decreases  while  bite  force  increases  during  light  midazolam  sedation,
and also  during  light  sedation  using  a  combination  of  midazolam  and  propofol.  Flumazenil  did
not antagonise  the  increase  in  bite  force  by  midazolam.  These  results  may  suggest  following
possibilities;  (1)  Activation  of  peripheral  benzodiazepine  receptors  located  within  the  temporo-
mandibular  joint  region  and  masticatory  muscles  may  be  the  cause  of  increasing  bite  force.  (2)
Propofol limited  the  long-latency  exteroceptive  suppression  (ES2)  period  during  jaw-opening
reflex. Thus,  control  of  masticatory  muscle  contraction,  which  is  thought  to  have  a  negative
feedback  effect  on  excessive  bite  force,  may  be  depressed  by  propofol.
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1. Introduction
Intravenous  sedation  is  useful  for  reducing  anxiety  and
fear  in  patients  undergoing  dental  treatment.  It  is  used
in  patients  with  dental  phobia,  gag  reflex  and  for  behav-
ior  modification  in  special  needs  patients  undergoing  dental
treatment  [1—3].  Midazolam  and  propofol  are  most  com-
monly  used  for  intravenous  sedation  today.  Midazolam  has
sedative,  anxiolytic  and  amnesic  effects  and  may  be  use-
ful  for  reducing  fear  and  anxiety  [4].  Propofol  has  sedative
and  antiemetic  effects  [5]  and  has  a  short  context-sensitive
half-time  that  allows  for  rapid  awakening  and  recovery  of
consciousness  [6].  In  recent  years,  intravenous  sedation  by
a  combination  of  midazolam  and  propofol  has  become  more
common  in  the  clinical  setting,  because  a  reliable  sedative
effect  can  be  achieved  at  lower  doses  of  propofol  when
used  with  midazolam  than  that  of  propofol  alone  [7—10]  and
patients  recover  from  sedation  faster.
Patients  with  dental  phobia  occasionally  clench  their
teeth  with  extreme  force  during  relatively  light  sedation
with  midazolam  or  propofol.  As  a  result,  dentists  sometimes
experience  difficulties  in  opening  their  mouth.  Patients  with
intellectual  disabilities  or  autistic  spectrum  disorder  occa-
sionally  show  unintended  body  movements  during  dental
treatment  under  intravenous  sedation.  As  a  result,  dentists
sometimes  suffer  from  control  behavioural  management  of
patients.  There  have  been  a  number  of  detailed  studies  on
central  nervous  system  (CNS)  effects,  circulatory  and  respi-
ratory  effects,  and  wakening  with  intravenous  sedation  by
midazolam  or  propofol  [11—18],  however,  only  few  studies
assessing  physical  movement  or  muscle  power  during  seda-
tion  [19,20].
This  article  reviews  the  effect  of  intravenous  sedation
with  midazolam  and  propofol  on  muscle  power  (bite  force,
grip  strength)  in  healthy  adult  volunteers,  and  discusses  its
clinical  significance.
2. Gamma ()-aminobutyric acid (GABA)
receptors and intravenous sedatives
GABA  receptors,  which  are  activated  by  the  CNS  inhibitory
neurotransmitter  GABA,  can  be  classified  into  three  types:
Figure  1  Schematic  representation  of  the  GABAA receptor,
which is  ligand-activated  chloride  channel  compromised  of
five transmembrane  subunits,  and  its  associated  binding  sites.
GABAA receptors  are  formed  by  different  pentameric  combina-
tion of  two  ,  two    and  one    subunits.  The  benzodiazepine
binding  site  is  located  at  between    and    subunits.  Anesthetic
agents  as  propofol  bind  to  sites  in  the  membrane-spanning
transmembrane  regions  between    and    subunits.
GABAA,  GABAB,  and  GABAC receptors.  GABAA receptors  are
inhibitory  ligand-gated  ion  channels  widely  present  in  the
CNS.  GABAA receptors  consist  of  a  pentameric  ion-channel
receptor  comprising  any  five  of  the  19  types  of  subunit:  1-
6,  1-3,  γ1-3,  ,  , ,  , and  1-3.  At  least  85%  of  GABAA
receptors  consist  of  a combination  of  12γ2,  23γ2,  or
31-3γ2  [21,22]  (Fig.  1).
Intravenous  sedatives,  both  midazolam  and  propofol  act
on  the  GABAA receptor  to  allow  selective  permeation  of
chlorine  ions,  resulting  in  hyperpolarization  of  the  synaptic
membrane  and  inhibition  of  nerve  transmission.  Different
combinations  of  subunits  in  the  GABAA receptors  result  in
different  drug  sensitivities.  Benzodiazepines  bind  to  the
benzodiazepine  site  (benzodiazepine  receptor)  located  on
the  border  between  the  1,  2,  3,  5  subunits  and  the  γ  sub-
unit  [23],  producing  sedative,  amnestic,  and  anticonvulsive
effects  at  1;  anxiolytic  and  muscle  relaxant  effects  at  2;
and  muscle  relaxant  effects  at  3  and  5  [24]  (Table  1).
Intravenous  anesthetics  including  propofol,  the  binding  site
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Figure  2  BIS  and  OAA/S  score  decreased  after  propofol  administration  dose-dependent  manner.Grip  strength  slightly  increased  at
the predicted  effect  site  propofol  concentration  of  1.2  	g/mL  or  less,  and  bite  force  dose-dependently  increased.  Bite  force  reached
the maximum  (50%  increase  from  the  baseline)  at  the  predicted  effect  site  propofol  concentration  of  1.6  	g/mL.  At  the  predicted
effect site  propofol  concentration  of  2.0  	g/mL,  both  muscle  powers  began  to  decrease.  Data  are  presented  as  mean  ±  standard
deviation (n  =  14).  *P  <  0.05  versus  before  propofol  administration.  Modified  from  reference  number  27.
Table  1  Effects  of  each  alpha  subunit  of  the  GABAA
receptor.
Subunit  Effects  Adverse  effects
1  Sedative,  Amnestic,
Anticonvulsive
Amnestic,  Addiction
2 Anxiolytic,  Muscle
relaxant
3 Muscle  relaxant
4, 6  Enhancement  of
benzodiazepine
5 Muscle  relaxant  Amnestic,  Tolerance
of  which  spans  the  1  and  2  subunits,  act  on  this  site  to
produce  hypnotic  effects  [25].  Previous  study  has  now  shown
that  propofol  binds  and  acts  on  transmembrane  (TM)  site
TM2  and  TM3  of  the    subunits  but  does  not  affect  the  
subunits  [26].  This  suggests  that  benzodiazepines  suppress
muscle  power  whereas  propofol  does  not;  however,  in  the
clinical  setting  during  light  intravenous  sedation,  dentists
often  experience  tension  in  the  masseter  muscles  and  body
movements  that  are  difficult  to  control.
3. Sthenometry researches during
intravenous sedation
3.1.  Muscle  power  measured  during  propofol
sedation  [27]
Twenty  healthy  right-handed  male  volunteers  (mean  age:
27.3  ±  2.0  years,  mean  height:  171.2  ±  4.9  cm,  and  mean
body  weight  65.3  ±  9.2  kg)  classified  in  American  Society
of  Anesthesiologists  (ASA)  physical  status  1  participated  in
this  study.  The  subjects  who  had  any  history  of  neuro-
logic,  cardiac,  pulmonary,  hepatic  or  renal  diseases,  mental
disorders,  or  drug  addiction  were  excluded.  Each  subject
underwent  2  experiments  with  at  least  a  1-week  interval  in
a  randomized  crossover  manner.  Sample  size  was  based  on
data  for  grip  strength  and  bite  force  obtained  from  a  pilot
study.  A  power  analysis  (˛  =  0.05,  ˇ  =  0.20)  before  the  pilot
study  suggested  that  each  group  of  at  least  16  subjects  would
be  required  to  detect  a  15%  difference  in  the  mean  bite
force.  Therefore,  20  subjects  were  recruited  to  allow  for  a
10%  dropout  rate.  Participants  were  asked  to  sit  on  a  dental
chair  with  the  Frankfurt  horizontal  plane  parallel  to  the  floor
surface.  One  percent  propofol  solution  was  administered
by  target-controlled  infusion  (TCI).  Predicted  effect-site
propofol  concentrations  were  set  at  0.4,  0.8,  1.2,  1.6,  and
2.0  	g/mL.  Measurements  prior  to  propofol  administration
were  defined  as  baseline  values.  After  each  concentration
was  maintained  for  15  min,  the  bispectral  index  (BIS)  and  the
observer’s  assessment  of  alertness/sedation  scale  (OAA/S)
were  used  to  evaluate  the  level  of  sedation,  while  grip
strength  and  bite  force  were  measured  to  evaluate  mus-
cle  power.  For  intragroup  comparison,  repeated  measures
ANOVA  was  used  for  grip  strength  and  bite  force  as  para-
metric  variables  and  followed  by  Dunnett’s  post-hoc  test.
Friedman’s  
2 test  was  used  for  OAA/S,  BIS  nonparamet-
ric  variables.  For  intergroup  comparisons,  Student  t  test
for  paired  samples  was  used.  A  P  value  less  than  0.05
was  considered  statistically  significant.  Significant  dose-
dependent  reductions  relative  to  baseline  measurements
were  observed  in  both  the  BIS  and  OAA/S  score  (Fig.  2).  Grip
strength  was  observed  to  increase  up  to  a  predicted  effect-
site  concentration  of  0.8  	g/mL,  but  declined  at  higher
concentrations.  Bite  force  was  observed  to  increase  up  to  a
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Figure  3  Relationship  between  BIS  value  and  grip  strength  (A).  Weak  correlation  between  BIS  value  and  grip  strength  was  observed.
y =  0.33x  +  13.4,  r2 =  0.16.  Relationship  between  BIS  value  and  bite  force  (B).  Weak  correlation  between  BIS  value  and  bite  force  was
observed. y  =  −6.54x  +  1424.3,  r2 =  0.13.  n  =  14.
predicted  effect-site  concentration  of  1.6  	g/mL,  and  then
declined  at  2.0  	g/mL,  though  the  value  was  higher  than
at  baseline  (Fig.  2).  The  results  suggested  that  under  light
sedation  using  propofol,  grip  strength  increases  slightly  and
bite  force  increases  in  a  dose-dependent  manner.  There  are
weak  correlations  between  BIS  value  and  grip  strength/bite
force  were  observed  (Fig.  3).
3.2.  Muscle  power  measured  during  midazolam
sedation  [28]
This  investigation  examined  the  effect  of  mild  intravenous
sedation  with  midazolam  on  muscle  power  and  the  change
in  muscle  power  due  to  administration  of  the  antagonist
flumazenil.  Twenty  healthy  right-handed  male  volunteers
(mean  age:  27.7  ±  2.3  years,  mean  height:  170.5  ±  5  cm,
and  mean  body  weight  66.6  ±  10  kg)  classified  in  American
Society  of  Anesthesiologists  (ASA)  physical  status  1  partic-
ipated  in  this  study.  The  subjects  who  had  any  history  of
neurologic,  cardiac,  pulmonary,  hepatic,  or  renal  disease,
mental  disorders  or  drug  addiction,  and  dysfunction  of  the
upper  limbs  were  excluded.  Each  volunteer  underwent  2
experiments  with  at  least  a  1-week  interval  in  a  random-
ized  crossover  manner.  Sample  size  was  based  on  data  for
grip  strength  and  bite  force  obtained  from  a  pilot  study.
A  power  analysis  (˛  =  0.05,  ˇ  =  0.20)  before  the  pilot  study
suggested  that  each  group  of  at  least  16  subjects  would
be  required  to  detect  a  15%  difference  in  the  mean  bite
force.  Therefore,  20  subjects  were  recruited  to  allow  for
a  10%  dropout  rate.  Participants  were  asked  to  sit  on  a
dental  chair  with  the  Frankfurt  horizontal  plane  parallel  to
the  floor  surface.  Measurements  prior  to  midazolam  admin-
istration  were  defined  as  baseline  values.  The  BIS,  OAA/S
score,  grip  strength,  and  bite  force  were  measured  at  2,  5,
10,  20,  and  30  min  after  intravenous  bolus  administration  of
0.05  mg/kg  midazolam.  Subsequently,  0.5  mg  flumazenil  was
administered  30  min  after  midazolam  administration  and  the
same  measurements  were  observed  5,  10,  and  20  min  later.
For  intragroup  comparison,  repeated  measures  ANOVA  was
used  for  grip  strength  and  bite  force  as  parametric  variables
and  followed  by  Dunnett’s  post-hoc  test.  Friedman’s  
2 test
was  used  for  OAA/S,  BIS  nonparametric  variables.  For  inter-
group  comparisons,  Student  t  test  for  paired  samples  was
used.  A  P  value  less  than  0.05  was  considered  statistically
significant.  A  slight  reduction  in  both  the  BIS  and  OAA/S
score  was  observed  after  midazolam  administration,  with
the  maximum  decrease  observed  at  5  min  after  midazolam
administration.  There  was  a gradual  recovery  thereafter  and
a  rapid  recovery  to  baseline  levels  after  flumazenil  admin-
istration  (Fig.  4).  Grip  strength  was  observed  to  decrease
after  midazolam  administration,  with  the  maximum  reduc-
tion  observed  at  5  min  after  midazolam  administration  (a
reduction  of  approximately  20%).  Grip  strength  rapidly
recovered  to  the  baseline  level  after  flumazenil  administra-
tion.  Bite  force  increased  after  midazolam  administration,
with  the  maximum  increase  also  observed  at  5  min  after
midazolam  administration  (an  increase  of  approximately
40%).  Bite  force  gradually  decreased  after  flumazenil  admin-
istration,  but  remained  significantly  increased  compared
with  baseline  at  20  min  after  flumazenil  administration
(Fig.  4).  With  intravenous  sedation  by  midazolam,  grip
strength  decreased  immediately  after  midazolam  admin-
istration  whereas  bite  force  increased.  The  results  also
suggested  that  the  increased  bite  force  is  maintained  and
not  antagonized  after  flumazenil  administration.
3.3.  Muscle  power  measured  during  combination
use of  midazolam  and  propofol  for  sedation  [29]
Twenty  healthy  right-handed  male  volunteers  (mean  age:
27.5  ±  1.8  years,  mean  height:  170.6  ±  5.2  cm,  and  mean
body  weight  66.9  ±  9.4  kg)  classified  in  American  Society
of  Anesthesiologists  (ASA)  physical  status  1  participated  in
this  study.  Subjects  were  not  studied  if  they  had  a  history
of  respiratory  or  circulatory  disease  or  any  disturbance  of
upper-limb  mobility.  Each  volunteer  underwent  2  exper-
iments  with  at  least  a  1-week  interval  in  a  randomized
crossover  manner.  Sample  size  was  based  on  data  for  grip
strength  and  bite  force  obtained  from  a  pilot  study.  Sam-
ple  size  was  based  on  data  for  grip  strength  and  bite  force
obtained  from  a  pilot  study.  A  power  analysis  (˛  =  0.05,
ˇ  =  0.20)  before  the  pilot  study  suggested  that  each  group
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Figure  4  BIS  and  OAA/S  score  decreased  after  midazolam  administration.  BIS  and  OAA/S  score  gradually  and  quickly  recovered,
respectively  after  flumazenil  administration.  R5,  5  min  after  reversal  with  flumazenil  administration;  R10,  10  min  after  reversal
with flumazenil  administration;  R20,  20  min  after  reversal  with  flumazenil  administration.  Grip  strength  decreased  after  midazolam
administration  and  recovered  after  flumazenil  administration.  Bite  force  increased  after  midazolam  administration  and  remained
increased even  after  flumazenil  administration.  R5,  5  min  after  reversal  with  flumazenil  administration;  R10,  10  min  after  reversal
with flumazenil  administration;  R20,  20  min  after  reversal  with  flumazenil  administration.  Data  are  presented  as  mean  ±  standard
deviation (n  =  20).  *P  <  0.05  versus  midazolam  administration.  Modified  from  reference  number  28.
Figure  5  BIS  and  OAA/S  score  significantly  decreased  during  sedation  but  recovered  to  baseline  levels  after  flumazenil  administra-
tion. R5,  5  min  after  reversal  with  flumazenil  administration;  R10,  10  min  after  reversal  with  flumazenil  administration;  R20,  20  min
after reversal  with  flumazenil  administration;  R30,  30  min  after  reversal  with  flumazenil  administration.  Grip  strength  decreased  by
approximately 25%  during  sedation  and  returned  to  baseline  level  after  flumazenil  administration.  Bite  force  increased  by  approx-
imately 84%  during  sedation.  Although  bite  force  reduced  after  flumazenil  administration,  it  remained  above  baseline  throughout
the experimental  period.  R5,  5  min  after  reversal  with  flumazenil  administration;  R10,  10  min  after  reversal  with  flumazenil  admin-
istration; R20,  20  min  after  reversal  with  flumazenil  administration;  R30,  30  min  after  reversal  with  flumazenil  administration.  Data
are presented  as  mean  ±  standard  deviation  (n  =  20).  *P  <  0.05  versus  baseline;  †p  <  0.05  versus  control.  Modified  from  reference
number 29.
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of  at  least  16  subjects  would  be  required  to  detect  a  15%
difference  in  the  mean  bite  force.  Therefore,  20  subjects
were  recruited  to  allow  for  a  10%  dropout  rate.  Partici-
pants  were  asked  to  sit  on  a  dental  chair  with  the  Frankfurt
horizontal  plane  parallel  to  the  floor  surface.  A  bolus  of
0.02  mg/kg  midazolam  was  administered  intravenously  and
thereafter  1%  propofol  solution  was  administered  by  using
TCI  so  that  the  predicted  effect-site  concentration  was
kept  at  1.0  	g/mL.  The  administration  was  maintained  for
30  min.  Subsequently,  0.5  mg  flumazenil  was  given  to  antag-
onize  the  effect  of  midazolam.  In  the  control  group,  only
physiological  saline  solution  was  administered.  Measure-
ments  prior  to  administration  were  defined  as  baseline  and
control  values.  The  BIS,  OAA/S  score,  grip  strength,  and  bite
force  were  measured  at  5,  10,  15,  20,  and  30  min  after  mida-
zolam  administration  as  well  as  at  5,  10,  20,  and  30  min
after  propofol  administration  was  stopped  and  flumazenil
was  administered;  and  in  the  control  group  before  admin-
istration  and  at  5,  10,  15,  20,  30,  35,  40,  50,  and  60  min
after  administration  of  physiological  saline  solution.  Sig-
nificant  reductions  in  both  the  BIS  and  OAA/S  score  were
observed  under  sedation  and  a  rapid  recovery  was  observed
after  flumazenil  administration  (Fig.  5).  Friedman’s  Fried-
man’s  
2 test  was  used  for  OAA/S,  BIS,  and  grip  strength  and
bite  force.  For  intergroup  comparisons,  the  Wilcoxon  signed-
rank  test  with  Bonferroni  correction  was  used.  A  p  value  of
less  than  0.05  was  considered  statistically  significant.
Grip  strength  decreased  by  up  to  approximately  30%
under  sedation  and  rapidly  recovered  to  the  same  level
as  baseline  after  flumazenil  administration.  Bite  force
increased  by  up  to  approximately  80%  under  sedation.  How-
ever,  only  bite  force  decreased  gradually  after  flumazenil
administration  and  remained  significantly  elevated  com-
pared  with  baseline  (Fig.  5).  The  results  suggested  that
during  intravenous  sedation  by  combined  use  of  midazolam
and  propofol,  grip  strength  decreases  in  the  same  manner
as  for  midazolam  alone,  whereas  bite  force  increases  in
an  additive  fashion  compared  with  that  during  sedation  by
either  midazolam  or  propofol  alone.
3.4.  Limitation  of  research
There  are  several  limitations  to  these  studies.  First,  because
this  study  enrolled  healthy  young  volunteers,  there  are  some
limitations  to  extrapolate  the  results  of  this  study  to  the
patients.  Second,  the  studies  were  not  completely  blinded
because  the  subjects  in  the  control  group  received  saline
solution  instead  of  midazolam,  propofol,  and  flumazenil.
However,  in  the  propofol  group,  the  infusion  pump  was
placed  in  the  blind  side  of  the  subject  and  the  intravenous
line  was  placed  in  the  blinded  side  of  the  subject,  and  other
conditions  were  set  in  the  same  way  between  each  group.
Third,  subjects  in  the  control  group  received  acetated
Ringer’s  solution  and  placebo  was  not  used  in  this  study
because  it  compared  several  variables  under  sedative  con-
ditions  or  non-sedative  conditions.  In  addition,  because  side
effects  such  as  agitation  may  occur  following  administration
of  flumazenil,  the  Clinical  Research  Ethics  Committee  did
not  approve  the  administration  of  flumazenil  to  the  control
group.
4. Discussion of the effects of intravenous
sedatives on muscle power
4.1.  Effect  of  propofol  on  skeletal  muscles
Tsai  et  al.  [27]  reported  that  grip  strength  slightly  increased
at  the  predicted  effect  site  propofol  concentration  of
1.2  	g/mL  or  less.  A  previous  study  has  reported  that
propofol  blocks  sarcolemmal  sodium  channels  on  skeletal
muscle  at  clinically  relevant  concentrations  while  maintain-
ing  potentials  close  to  the  physiological  resting  potential
[30]  and  this  mechanism  may  contribute  to  the  decrease
in  muscle  excitability.  It  is  suggested  that  low-dose  propo-
fol  (light  sedation  level)  may  not  be  enough  to  block  sodium
channel.  However,  there  is  no  study  on  the  increase  in  mus-
cle  power  by  propofol,  while  propofol  at  induction  doses
reduce  muscle  tone  [31,32].
4.2.  Effect  of  midazolam  on  skeletal  muscles
Huang  et  al.  [28]  reported  that  grip  strength  decreased
immediately  after  administration  of  midazolam,  while  it
recovered  rapidly  with  the  administration  of  flumazenil.  The
benzodiazepine  such  as  midazolam  acts  on  the  ˛2  subunit
of  the  GABAA receptor,  producing  a centrally  acting  mus-
cle  relaxant  effect  in  the  skeletal  muscles  [24,33—35].  This
may  be  partly  involved  in  the  reduction  in  grip  strength
during  sedation.  The  sedative  effects  of  midazolam  last  for
20—30  min,  with  the  maximum  effect  occurring  at  2—5  min
after  administration  [36].  Tomita  et  al.  [29]  reported  that
the  muscle  relaxant  effects  produced  by  midazolam  seda-
tion  offset  the  increase  in  grip  strength  caused  by  propofol
sedation  and  that  this  effect  was  maintained  throughout
sedation.  If  the  muscle  relaxant  and  sedative  effects  of
midazolam  exhibit  similar  pharmacological  changes,  there
should  have  been  a  gradual  recovery  in  the  grip  strength
that  had  decreased  in  patients  sedated  with  combined  use
of  midazolam  and  propofol.  In  other  words,  this  suggests
that  the  sedative  effects  of  midazolam  mediated  via  the  1
subunit  and  its  muscle  relaxant  effects  mediated  via  the  2
subunit  differ  pharmacodynamically,  even  if  both  are  medi-
ated  via  the  GABAA receptor.
4.3.  Hypothesis  of  bite  force  increase  after
midazolam  or  propofol  administration
4.3.1.  Increased  bite  force  during  non-anxious  (relaxed)
state
Bite  force  increased  when  patients  underwent  mild  intra-
venous  sedation  using  propofol  and  midazolam  [27—29].
One  possibility  is  that  the  relaxed  state  produced  by  mild
intravenous  sedation  increased  the  power  of  the  mastica-
tory  muscles.  However,  a  previous  study  on  enhancement
of  physical  function  by  drugs  showed  that  alcohol  intake
reduces  anxiety  but  does  not  enhance  motor  function  [37].
Furthermore,  in  a  study  on  benzodiazepine  intake  and  phys-
ical  capabilities  [38],  a  comparison  of  individuals  taking
temazepam  and  placebo  showed  no  significant  difference
in  muscle  power.  Therefore,  the  increased  bite  force  is
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Table  2  Characteristic  of  the  benzodiazepine  site  on  the  GABAA receptor.
Distribution  Antagonism  by
flumazenil
Muscle  relaxant  effect




Peripheral  benzodiazepine  site
Musculature
— Muscular  strength  improves  with  low
concentration  of  benzodiazepine?
Peripheral  organs
CNS
not  adequately  explained  by  the  hypothesis  that  relaxation
enhances  muscle  power.
4.3.2.  Sedation  may  inhibit  the  controls  of  occlusion
A  previous  study  [39]  has  shown  that  peripheral  GABAA
receptors  present  in  the  temporomandibular  joint  (TMJ)
region  in  rats  inhibit  nociceptive  signals  in  the  masticatory
muscles,  suggesting  that  peripheral  GABAA receptors  may  be
involved  in  the  increased  bite  force  in  humans  as  well.  Both
midazolam  and  propofol  act  on  peripheral  GABAA receptors
and  could  inhibit  nociceptive  signals  in  the  TMJ,  thereby
alleviate  excessive  bite  forces.  However,  as  far  as  bite  forces
are  concerned,  nociceptive  reflexes  to  noxious  stimuli  are
present  in  areas  other  than  the  TMJ,  such  as  in  the  peri-
odontal  membrane  and  masticatory  muscles;  currently,  it
is  unclear  how  these  reflexes  are  involved.  Furthermore,
because  the  increased  bite  force  under  sedation  remained
elevated  after  flumazenil  administration  and  did  not  recover
to  the  pre-sedation  level,  the  increase  in  bite  force  is  not
adequately  explained  by  nociceptive  inhibition  alone.
4.3.3.  Involvement  of  peripheral  benzodiazepine
receptors
Benzodiazepine  receptors,  which  together  with  GABAA
receptors  form  ion-channel  complexes,  can  be  categorized
into  central  or  peripheral  benzodiazepine  receptors.  The
central  benzodiazepine  receptors  are  distributed  in  areas
such  as  the  cerebral  cortex,  cerebellum,  and  hypothala-
mus,  whereas  the  peripheral  benzodiazepine  receptors  are
mostly  distributed  in  the  musculature  and  peripheral  organs
such  as  the  liver  and  kidneys,  although  they  are  also  found
in  the  CNS  [40].  The  role  of  the  peripheral  benzodiazepine
receptors  is  less  clear,  but  it  seems  that  they  are  connected
with  more  slowly  appearing  drug  actions,  such  as  modu-
lation  of  cell  proliferation  [41].  In  a  study  using  mouse
diaphragm  and  diaphragm  nerves,  activation  of  periph-
eral  benzodiazepine  receptors  by  ligands  was  reported
to  enhance  diaphragm  contraction  [42].  Midazolam  acts
on  both  central  and  peripheral  benzodiazepine  receptors,
while  the  antagonist  flumazenil  mainly  exhibits  an  affinity
for  central  benzodiazepine  receptors  [43].  Moreover,  one
study  has  shown  that  although  administration  of  0.5—1.0  mg
flumazenil  can  antagonize  the  sedative  effects  of  midazo-
lam,  it  cannot  completely  antagonize  the  disturbance  of
the  equilibrium  function  induced  by  midazolam  [44].  This
suggests  that  midazolam  enhances  bite  force  by  acting  on
the  peripheral  benzodiazepine  receptors  present  around  the
jaw  muscles.  However,  flumazenil  does  not  antagonize  this
effect.  These  results  are  consistent  with  those  of  Huang
et  al.  [28]  and  Tomita  et  al.  [29], and  could  partly  explain
the  increase  in  bite  force  during  midazolam  sedation  and
the  maintenance  of  this  effect  even  after  flumazenil  admin-
istration  (Table  2).
4.3.4.  Suppression  of  the  jaw-opening  reflex  by  propofol
Electrical  stimulation  of  the  trigeminal  nerve  suppresses  vol-
untary  contraction  of  the  masseter  muscle  and  temporalis
muscle  [45]. These  responses  are  referred  to  as  exterocep-
tive  suppression  (ES)  reflexes.  The  ES,  which  is  a  mechanism
for  nociception  defensive  reflexes  in  the  masticatory  mus-
cles,  is  involved  in  the  jaw-opening  reflex  that  a  brainstem
reflex  mediated  via  the  trigeminal  nerve.  The  short-latency
ES  component  is  termed  ES1  and  the  long-latency  compo-
nent  is  termed  ES2  [45].  Midazolam  does  not  suppress  ES
reflexes  mediated  by  the  upper  CNS,  while  propofol  has  been
reported  to  inhibit  ES2,  which  controls  masseter  muscle  con-
traction  in  the  brainstem  [45].  This  suggests  that  propofol
may  have  increased  bite  force  by  suppressing  the  mechanism
that  inhibits  jaw-closing  muscle  contraction,  which  presum-
ably  has  a negative  feedback  effect  against  excessive  bite
force  during  hard  biting.
In  the  clinical  setting,  dental  anesthesiologists  have  thus
far  managed  patients  incapable  of  controlling  their  body
movements  during  intravenous  sedation  (especially  patients
with  dental  phobia  or  special  needs)  by  increasing  seda-
tive  doses  and  ensuring  patients  are  more  heavily  sedated.
However,  this  may  be  an  inadequate  approach  to  manage
enhanced  bite  force.  Furthermore,  the  use  of  deep  seda-
tion  also  increases  the  risks  of  airway  management  and
other  issues.  For  patients  who  are  difficult  to  manage  under
standard  intravenous  sedation,  general  anesthesia  may  be  a
better  choice.
5.  Conclusion
(1)  Grip  strength  decreased  after  administration  of  mida-
zolam  during  light  sedation.  According  to  the  effects  of
˛2  subunit  of  the  GABAA receptor,  midazolam  produce
centrally  acting  muscle-relaxant  effect  in  the  skeletal
muscles.
(2)  Bite  force  increases  despite  the  muscle-relaxant  effect
of  midazolam  during  light  sedation.  Peripheral  GABAA
receptors  located  within  the  temporomandibular  joint
region  and  the  peripheral  benzodiazepine  receptors  in
the  masseter  muscle  may  be  partly  involved  in  this
increase.
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(3)  Grip  strength  decreased  whilst  bite  force  increased
under  light  sedation  using  a  combination  of  midazolam
and  propofol.  Activation  of  peripheral  benzodiazepine
receptors  in  the  masticatory  muscles  may  be  the  cause
of  this  sustained  increase.  Propofol  limited  ES2  during
jaw-opening  reflex.  Thus,  control  of  masticatory  muscle
contraction,  which  is  thought  to  have  a  negative  feed-
back  effect  on  excessive  bite  force,  may  be  depressed
by  propofol.
(4)  This  review  has  yet  to  fully  clarify  the  detailed  mecha-
nism  of  how  midazolam  and  propofol  increase  bite  force.
Further  studies,  including  animal  studies,  are  needed  to
examine  the  mechanism  of  how  intravenous  sedatives
enhance  muscle  power.
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